

Supplementary Data

Supplementary figures 1-6 and figure legends, and Supplementary tables 1-2

MutS β abundance and Msh3 ATP hydrolysis activity are important drivers of CTG•CAG repeat expansions

Norma Keogh¹, Kara Chan², Guo-Min Li^{2,3} and Robert S. Lahue^{1,4,*}

¹Centre for Chromosome Biology and ⁴NCBES Galway Neuroscience Centre

National University of Ireland Galway

Newcastle Road

Galway, Ireland

H91TK33

²Department of Toxicology and Cancer Biology, University of Kentucky College of Medicine, Lexington, KY 40536

³Department of Biochemistry and Molecular Biology, Norris Comprehensive Cancer Center, University of Southern California Keck School of Medicine, Los Angeles, CA 90033

*corresponding author

Legends to supplementary figures

Supplementary Figure 1. Schematic showing overview of shuttle vector assay and details of shuttle vectors used for measuring expansions and contractions. **(A)** Workflow of shuttle vector assay. SVG-A cells are seeded at 4.0×10^5 cells and transfected with the appropriate shuttle vector. The plasmid is harvested and purified after 48 hours, then transformed into *S. cerevisiae* as a biosensor. Yeast cells are plated onto SC-histidine plates for total transformants for both assays and onto SC-his-uracil plates for genetic selection for contraction assays. Replica plating onto canavanine plates (100 $\mu\text{g}/\text{ml}$) is required for genetic selection for expansion assay only. Colony counts and PCR confirmation are required to

calculate expansion/contraction frequency. **(B)** Schematic showing pBL302 reporter plasmid system used to measure CTG expansions. Expansion of ≥ 4 CTG repeats causes out of frame translation of the *CAN1* gene and confers canavanine resistance. In these studies, expansion of + 12 repeats was the largest expansion observed. **(C)** Reporter plasmid pBL247 is used to measure CTG contractions for the contraction assay. Contraction of CTG repeats from 33 repeats to ≤ 28 repeats causes an Ura⁺ phenotype, which allows genetic selection of contractions. A maximum contraction size of -30 CTG repeats was observed in these studies.

Supplementary Figure 2. Immunoblot analysis of *Msh3* variant cell lines with Msh3 C-terminal antibody, Abcam Ab154521, raised against amino acid positions 916-1137 of Msh3. **(A)** Immunoblot showing Msh3 protein expression in *Msh3*^{+/+} and *Msh3* variant cell lines. No detectable Msh3 expression in *Msh3*^{-/-} cell line, confirming knockout of *Msh3*. Second band, marked with *, is non-specific as noted by the manufacturer. **(B)** Schematic showing CRISPR/Cas9 target region and immunogen regions of both Msh3 antibodies used in screening cell lines.

Supplementary Figure 3. Growth curve analysis of *Msh3*^{-/-}, *Msh3*^{+/+} and *Msh3*^{1.7X} cell lines, showing no detectable difference in cell growth. Error bars denote \pm SEM, $n=3$.

Supplementary Figure 4. Estimation of MutS β abundance as fraction of overall MutS complexes in SVG-A cells. **(A)** Overview of experimental approach and calculation of Msh3/Msh2 capture efficiencies and MutS β abundance. FT stands for Flow-through. **(B)** Representative immunoblot of co-immunoprecipitated Msh3 and Msh2 showing IP input and IP flow-through from wild type SVG-A cells. In this example there was 11% of total Msh3 in flow-through, correspondingly the capture efficiency was calculated at 84%. For Msh2, 78%

was measured in flow-through, indicating that 22% of Msh2 protein was captured by the anti-Msh3 antibody. MutS β abundance is calculated using the formula $(22/84)*100\%$ to give a value of 27%. **(C)** Quantitative data of Msh3 and Msh2 capture efficiencies from co-IP data, average values shown \pm SEM, $n=4$.

Supplementary Figure 5. Characterisation of *Msh3*^{E976A} Walker B mutant cell line, in comparison to *Msh3*^{+/+} cell line. **(A)** Growth curve analysis of *Msh3*^{E976A} cells in comparison to *Msh3*^{+/+} showing no detectable defect in cell growth. $n=3$. **(B)** Quantitative analysis of immunoprecipitated Msh3 and Msh2 protein abundance normalised to protein input and relative to *Msh3*^{+/+} cells. A partial defect in MutS β complex formation is observed in *Msh3*^{E976A} cell lines. $n=3$, $*P=0.023$ for Msh3 and $P=1.5 \times 10^{-4}$ for Msh2. For both panels, error bars denote \pm SEM.

Supplementary Figure 6. Characterisation of Msh3 polymorphic cell lines in comparison to *Msh3*^{+/+} wild type cells. **(A)** Quantitative analysis of Msh protein expression normalised to actin and relative to *Msh3*^{+/+} cell line. *Msh3*^{T363I} add-back cell line has an average Msh3 expression level 75% that of wild type expression, while the value for *Msh3*^{T363I} add-back cell was 71% of control. $n=7$ for Msh3 wild-type or $n=4$ for polymorphic Msh3 proteins; $n=3-4$ for Msh2 and Msh6 protein levels in all cell lines. $*P = 0.035$ compared to Msh2 level in *Msh3*^{+/+} cells; and $**P=0.0085$, both compared to Msh6 level in *Msh3*^{+/+} cells. **(B)** Quantitative analysis of immunoprecipitated Msh3 and Msh2 protein abundance normalised to protein input and relative to *Msh3*^{+/+} cells. A decrease in immunoprecipitated Msh2 protein levels is observed in *Msh3*^{T363I} cells; $n=3$, $*P=0.004$; and in immunoprecipitated Msh2 protein levels is observed in *Msh3*^{T1045A} cells; $n=3$, $*P=0.005$. **(C)** Growth curve analysis of

Msh3^{T363I} and *Msh3*^{T1045A} cell lines in comparison to *Msh3*^{+/+} cells, showing no detectable difference in cell growth, $n=3$. For all panels, error bars denote \pm SEM.

Supplementary Table 1. Mutagenic primers were designed using NEBasechanger program (New England Biolabs). Primers were used in pairs to perform site-directed mutagenesis using the Q5 site-directed mutagenesis kit (New England Biolabs) to create *Msh3* ATPase and polymorphic variant cell lines. Mutagenic nucleotides are shown in bold and underline.

Supplementary Table 2. Values of n and P for all figures.

Figure S1

Overview of shuttle vector assay





Figure S2

A



B

Deletion in *Msh3*^{-/-}

Δ aa 116-118

Antibody

BD Msh3 611390

Abcam Msh3 Ab154521

Immunogen

Human Msh3 aa. 136-349

Human Msh3 aa. 916-1137

Figure S3





Figure S4

Estimation of MutSβ abundance

- A**
- Measure Msh3 capture efficiency

$$1 - \left(\frac{\text{Msh3}_{\text{FT}}/\text{Actin}_{\text{FT}}}{\text{Msh3}_{\text{Input}}/\text{Actin}_{\text{Input}}} \right) * 100\%$$
 - Measure Msh2 capture efficiency

$$1 - \left(\frac{\text{Msh2}_{\text{FT}}/\text{Actin}_{\text{FT}}}{\text{Msh2}_{\text{Input}}/\text{Actin}_{\text{Input}}} \right) * 100\%$$
 - MutSβ abundance = Msh2 capture efficiency / Msh3 capture efficiency



C

Protein	Capture efficiency	SEM	n
Msh3	84%	11%	4
Msh2	22%	6%	4
MutSβ abundance	26%	6%	4

Figure S5






Figure S6


A



B



C



Supplementary Table 1

Msh3 variant	Forward primer	Reverse primer
E975A	CTAGGAAGAGGGACGAGCACTCATG	GGC ATCCAAGATAACCAAGGACTGTGATG
T363I	ATGACTGAT ATI TCTACCAGCTATC	TATCTCATCAACATTTACAGC
T1045A	GAACAAGTCCCTGATTTTGTACCTTC	TGC GGC GCCTGGATCCAGTTTGCTTC

Supplementary Table 2

n and P values

Figure	Entry	Comparator	n	P value
1C	Msh3 abundance in Msh3 ^{-/-} cells	Msh3 abundance in Msh3 ^{+/+} cells	9	2.23E-20
1C	Msh2 abundance in Msh3 ^{-/-} cells	Msh2 abundance in Msh3 ^{+/+} cells	6	0.135
1C	Msh6 abundance in Msh3 ^{-/-} cells	Msh6 abundance in Msh3 ^{+/+} cells	6	0.058
1E	Expansion frequency in Msh3 ^{-/-} cells	Expansion frequency in Msh3 ^{+/+} cells	3 - 4	0.0019
1F	Contraction frequency in Msh3 ^{-/-} cells	Contraction frequency in Msh3 ^{+/+} cells	3	0.3
2B	Msh3 abundance in Msh3 1.7x cells	Msh3 abundance in Msh3 ^{+/+} cells	9	1.87E-06
2B	Msh2 abundance in Msh3 1.7x cells	Msh2 abundance in Msh3 ^{+/+} cells	5 - 7	0.082
2B	Msh6 abundance in Msh3 1.7x cells	Msh6 abundance in Msh3 ^{+/+} cells	5 - 7	0.032
2C	Expansion frequency in Msh3 1.7x cells	Expansion frequency in Msh3 ^{+/+} cells	3	0.163
2D	Contraction frequency in Msh3 1.7x cells	Contraction frequency in Msh3 ^{+/+} cells	3	0.209
2D	Contraction frequency in Msh3 2.9x cells	Contraction frequency in Msh3 ^{+/+} cells	3	0.290
2F	IP Msh3 abundance from Msh3 ^{-/-} cells	IP Msh3 abundance from Msh3 ^{+/+} cells	4	5.44E-13
2F	IP Msh2 abundance from Msh3 ^{-/-} cells	IP Msh2 abundance from Msh3 ^{+/+} cells	4	4.30E-11
2F	IP Msh3 abundance from Msh3 2.9x cells	IP Msh3 abundance from Msh3 ^{+/+} cells	4	1.66E-04
2F	IP Msh2 abundance from Msh3 2.9x cells	IP Msh2 abundance from Msh3 ^{+/+} cells	4	4.96E-03
3D	Expansion frequency in Msh3 E975A cells	Expansion frequency in Msh3 ^{+/+} cells	3	0.037
3E	Contraction frequency in Msh3 E975A cells	Contraction frequency in Msh3 ^{+/+} cells	4 - 5	0.065
3G	ATPase activity MutSβ-Msh3E976A minus DNA	ATPase activity wild type MutSβ minus DNA	3	0.028

Supplementary Table 2 continued

3G	ATPase activity MutS β - Msh3E976A plus DNA	ATPase activity wild type MutS β plus DNA	3	0.001
----	------------------------------------------------------	----------------------------------------------------	---	-------

Supplementary Table 2 continued

4D	Expansion frequency in Msh3 T363I cells	Expansion frequency in Msh3+/+ cells	3	0.300
4D	Expansion frequency in Msh3 T1045A cells	Expansion frequency in Msh3+/+ cells	3	0.289

Supp 5B	IP Msh3 abundance from Msh3 E975A cells	IP Msh3 abundance from Msh3 +/+ cells	3	0.023
Supp 5B	IP Msh2 abundance from Msh3 E975A cells	IP Msh2 abundance from Msh3+/+ cells	3	1.50E-04

Supp 6A	Msh3 T363I abundance	Msh3 wild type abundance	4 - 7	0.17
Supp 6A	Msh3 T1045A abundance	Msh3 wild type abundance	4 - 7	0.10
Supp 6A	Msh2 abundance from Msh3 T363I cells	Msh2 abundance from Msh3 +/+ cells	3 - 4	0.035
Supp 6A	Msh2 abundance from Msh3 T1045A cells	Msh2 abundance from Msh3 +/+ cells	3 - 4	0.13
Supp 6A	Msh6 abundance from Msh3 T363I cells	Msh6 abundance from Msh3 +/+ cells	3 - 4	0.0085
Supp 6A	Msh6 abundance from Msh3 T1045A cells	Msh6 abundance from Msh3 +/+ cells	3 - 4	0.075
Supp 6B	IP Msh3 abundance from Msh3 T363I cells	IP Msh3 abundance from Msh3 +/+ cells	3	0.38
Supp 6B	IP Msh3 abundance from Msh3 T1045A cells	IP Msh3 abundance from Msh3 +/+ cells	3	0.41
Supp 6B	IP Msh2 abundance from Msh3 T363I cells	IP Msh2 abundance from Msh3 +/+ cells	3	0.004
Supp 6B	IP Msh2 abundance from Msh3 T1045A cells	IP Msh2 abundance from Msh3 +/+ cells	3	0.005